EPS Chuangjian Technology (03860) issued an announcement. On November 29, 2023, the company's wholly-owned subsidiary...
According to the Zhitong Finance App, EPS Chuangjian Technology (03860) issued an announcement. On November 29, 2023, EPS Innovative Medicine (Japan) Co., a wholly-owned subsidiary of the company, EPS Innovative Medicine (Japan) Co., Ltd. Ltd. (as the buyer) enters into a share transfer agreement with the seller. The buyer has agreed to the acquisition on conditions and the seller has conditionally agreed to sell the shares to be sold (the issued share capital of the target company, Biotube Co., Ltd., is about 47.3%). The cost of the acquisition was 612 million yen (equivalent to approximately HK$31,8361 million), to be paid in cash by the buyer.
On November 29, 2023, the target company (as the issuer) and EPS Innovative Medicine (Japan) Co., a wholly-owned subsidiary of the company Ltd. (as the subscribing party) entered into a subscription agreement relating to the subscription of convertible bonds with a capital of 150 million yen (equivalent to approximately HK$7.8 million).
On January 29, 2024, the second batch of delivery terms were met; the share transfer and subscription of convertible bonds were completed in accordance with the share transfer agreement; the company acquired the target company's shares through its wholly-owned subsidiary (i.e. EPS Innovative Medicine) and converted the convertible bonds into the target company's share capital; and immediately after the conversion of convertible bonds, the company indirectly held 51.0% of the target company's issued share capital, and the target company would become a subsidiary of the company, and the financial performance, assets and liabilities of the financial group would be merged into the group Financial statements.